Cancer/Oncology News

State-of-the-Art Lecture: What Are The Most Important Ongoing Clinical Trials In Urologic Oncology Worldwide?

Mon, 23 Jun 2008 11:40:04 GMT

ORLANDO, FL (UroToday.com) - Dr. Crawford presented information on challenges facing clinical trials from SWOG, ECOG and CALGB.

Full text

5 Top Young Clinical Investigators Receive Damon Runyon Cancer Research Foundation Awards

Mon, 23 Jun 2008 11:40:04 GMT

The Damon Runyon Cancer Research Foundation named 5 new Damon Runyon Clinical Investigators at its May 2008 Clinical Investigator Award Committee review.

Full text

State-of-the-Art Lecture: Aptomers Of Nanotechnology - Reported From The Annual Meeting Of The American Urological Association

Mon, 23 Jun 2008 11:40:03 GMT

ORLANDO, FL (UroToday.com) - Dr. Omid Farokhzad from Harvard addressed nanotechnology. Nanotechnology is the assembly of particles.

Full text

AAD, MLB And MLB Players Association Play Sun Smart To Strike Out Skin Cancer

Sun, 22 Jun 2008 08:20:04 GMT

Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) are teaming up with the American Academy of Dermatology (Academy) this summer through the Play Sun SmartTM program to educate players and fans about skin cancer.

Full text

Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented At The 20th EORTC-NCI-AACR Symposium

Sun, 22 Jun 2008 08:20:03 GMT

Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M.

Full text

CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab Erbitux

Sat, 21 Jun 2008 05:00:09 GMT

Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.

Full text

Merck Applies To Extend Use Of Erbitux For 1st-Line Head And Neck Cancer In Europe

Sat, 21 Jun 2008 05:00:08 GMT

Merck KGaA announced that it has submitted an application to the European Medicines Agency (EMEA) to broaden the use of the targeted therapy Erbitux (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Full text

Indiana University Simon Cancer Center Priority: Reduce Cancer Incidences, Mortality Among State's Diverse Populations

Sat, 21 Jun 2008 05:00:07 GMT

Cancer knows no boundaries. It strikes men and women. Rich and poor. Young and old. One difference, however, is the frequency and severity of the disease when diagnosed.

Full text

Melanoma Is On The Rise In Women

Sat, 21 Jun 2008 05:00:07 GMT

Over the past few decades, the incidence of melanoma, the deadliest from of skin cancer, has increased.

Full text

Obesity Surgery May Reduce Cancer Risk

Sat, 21 Jun 2008 05:00:06 GMT

Two studies from Canada and Brazil announced at conferences earlier this week suggest that bariatric or weight-loss surgery to control obesity may also cut cancer risk.

Full text